276 filings
Page 3 of 14
8-K
1hpjbsr 87tmu
10 Jun 21
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
knwvh0 7899omsr
5 May 21
Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results
4:06pm
8-K
hgdsl2c0ix 0v46
25 Feb 21
Departure of Directors or Certain Officers
7:01am
8-K
6wlt4v
10 Feb 21
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year
4:08pm
8-K
pjgf144pk6
2 Dec 20
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
7:02am
8-K
eak2p86o csh
28 Oct 20
Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
4:05pm
8-K
frny3rxn9lrb
18 Aug 20
Vanda Pharmaceuticals’ Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
5:18pm
8-K
zngkr5nm04oz
5 Aug 20
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
4:06pm
8-K
nyiflhy jxw
29 Jul 20
Departure of Directors or Certain Officers
4:20pm
8-K
dd8g ysfipdvoy
11 Jun 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
c39dnd ambaan
26 May 20
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
7:11am
8-K
pgp8kgj
13 May 20
Other Events
7:43am
8-K
p0sytg2sdn7 01gg
6 May 20
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results
4:16pm
8-K
kgvyq17g5i uy2qudhu0
13 Mar 20
Other Events
5:17pm
8-K
nwj1 62ozv3
3 Mar 20
Departure of Directors or Certain Officers
4:30pm
8-K
sv0rb
26 Feb 20
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
8:54am
8-K
92wjx1 pdw18y
25 Feb 20
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
4:07pm
8-K
2ten f1dmn3zi
20 Feb 20
Departure of Directors or Certain Officers
4:30pm
8-K
iyv659
19 Feb 20
Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors
6:12am
8-K
pugri6w3jsgy4sy
3 Feb 20
Other Events
6:15am